左心室の質量と,抗高血圧治療への反応の評価
Lancet (London, England)
|February 27, 1982
まとめ
エッセンシャル高血圧は,左心房 (LV) 質量と有意に相関しています. 抗高血圧療法により,高血圧患者の血圧とLV質量の両方が効果的に低下します.
科学分野:
- 心臓病学 心臓病学
- 高血圧の研究 高血圧の研究
- 診断用イメージング
背景:
- エッセンシャル高血圧は,心血管合併症に関連する一般的な状態です.
- 左心室 (LV) ハイパルトロフィーは,高血圧患者における心血管疾患の有意な予測因子である.
- エコーカルディオグラフィは,心臓の構造と機能を評価するための重要なツールです.
研究 の 目的:
- 主要高血圧の患者における血圧と左心房質量との関係を調査する.
- 抗高血圧療法の血圧とLV質量に対する効果を評価する.
主な方法:
- Mモードエコーカルディオグラフィーと継続的な動脈内外通行式血圧モニタリングを使用しました.
- 左心室質量指数は,エコーカルディオグラフィのデータから計算した.
- 患者は繰り返しエコーカルディオグラフィーと血圧測定で追跡された.
主要な成果:
- 24時間の平均シストリック血圧は,エコーカルディオグラフィのLV質量と有意な相関を示した.
- 抗高血圧療法により,未治療患者と比較して,血圧とLV質量指数の両方が著しく低下しました.
- 治療を受けたグループでは,シストリック血圧の低下とLV質量指数との間に強い相関が観察されました.
結論:
- 静脈収縮血圧は,左心房縮の病原性において決定的な役割を果たします.
- エコカルジオグラフィで評価された LV 質量の変化は,高血圧患者における血圧の変化と相関しています.
- 抗高血圧治療は,高血圧に関連した心臓の構造的変化を逆転させることができます.
関連する概念動画
Mitral Valve Prolapse II: Assessment and Management
IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular tachycardia.
Mitral Regurgitation III: Medical Management
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
Mitral Stenosis II: Clinical features and Diagnostic Tests
Mitral stenosis is a heart condition in which the mitral valve, which allows blood to flow from the left atrium to the left ventricle, becomes narrowed or stenotic. This narrowing hinders blood flow and leads to clinical symptoms requiring specific medical evaluations and management strategies. The following overview outlines the clinical symptoms, assessments, diagnostic findings, prevention methods, and treatments for mitral stenosis.Clinical ManifestationsDyspnea (shortness of breath): This...
Aortic Regurgitation III: Medical Management
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...


